SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure

Huijun Gu1,2, Jianpei Wen3, Yiyi Liu1

  • 1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Institute of Advanced Clinical Medicine, Peking University; National Health Commission (NHC) Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Beijing Key Laboratory of Cardiovascular Receptors Research; Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing 100191, China (H.G., Y.L., Y.X., M.Z., L.B., H.C., W.Z., W.X., K.W., Y.D., X.Y., H.W., J.H., E.D., Y. Zhang, H.X.).

Circulation
|May 22, 2026
PubMed

Insights

Sterol regulatory element-binding protein 1 (SREBP1) directly activates sodium-hydrogen exchanger 3 (NHE3) in heart failure with reduced ejection fraction (HFrEF). This leads to calcium handling dysregulation and impaired cardiac contractility, identifying a new therapeutic target for HFrEF.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Heart Failure Pathophysiology

Background:

  • Heart failure with reduced ejection fraction (HFrEF) involves impaired cardiac contractility and high mortality, linked to intracellular ion cycling dysregulation.
  • Mechanisms connecting myocardial stress to ion dysregulation in HFrEF are not fully understood.
  • The role of metabolic transcription factor SREBP1 in HFrEF, particularly ion handling without metabolic comorbidities, remains undefined.

Purpose of the Study:

  • To investigate the role of sterol regulatory element-binding protein 1 (SREBP1) in the pathophysiology of heart failure with reduced ejection fraction (HFrEF).
  • To determine if SREBP1 directly influences ion handling, specifically the sodium-hydrogen exchanger 3 (NHE3), in the failing heart.
  • To explore the therapeutic potential of targeting the SREBP1-NHE3 pathway in HFrEF.

Main Methods:

  • Analysis of cardiac tissues from HFrEF patients and mice with transverse aortic constriction (TAC)-induced HFrEF.
  • Generation of cardiomyocyte-specific SREBP1 transgenic (Srebp1a-Tg) and knockdown (Cre-Srebp1f/f) mouse models.
  • Utilized AAV9 vectors for manipulating NHE3 and SREBP1 expression in cardiomyocytes to validate findings.

Main Results:

  • SREBP1 was activated in human and mouse HFrEF hearts, directly transactivating the sodium-hydrogen exchanger 3 (NHE3) gene.
  • SREBP1 activation led to impaired cardiac contractility and dysregulated calcium handling, associated with increased NHE3 activity.
  • Knockdown of SREBP1 or NHE3 in cardiomyocytes restored calcium handling and improved cardiac function in HFrEF models.

Conclusions:

  • SREBP1 directly upregulates cardiac NHE3 during HFrEF progression, causing ion dysregulation and contractile dysfunction.
  • This study reveals a novel, noncanonical role for SREBP1 in heart failure pathophysiology.
  • The SREBP1-NHE3 axis represents a potential new therapeutic target for HFrEF.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...